

# Amparo Snchez-Navarro

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/4450241/amparo-sanchez-navarro-publications-by-year.pdf>

**Version:** 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

25  
papers

400  
citations

11  
h-index

19  
g-index

26  
ext. papers

465  
ext. citations

5.4  
avg, IF

3.22  
L-index

#	Paper	IF	Citations
25	Xanthan Gum-Konjac Glucomannan Blend Hydrogel for Wound Healing. <i>Polymers</i> , <b>2020</b> , 12,	4.5	26
24	Sildenafil Citrate Liposomes for Pulmonary Delivery by Ultrasonic Nebulization. <i>Applied Sciences (Switzerland)</i> , <b>2018</b> , 8, 1291	2.6	3
23	Lyophilized tablets for focal delivery of fluconazole and itraconazole through vaginal mucosa, rational design and in vitro evaluation. <i>European Journal of Pharmaceutical Sciences</i> , <b>2018</b> , 122, 144-151	5.1	2
22	Albumin micro/nanoparticles entrapping liposomes for itraconazole green formulation. <i>European Journal of Pharmaceutical Sciences</i> , <b>2017</b> , 106, 159-165	5.1	5
21	Development and In Vitro Evaluation of a Novel Drug Delivery System (Albumin Microspheres Containing Liposomes) Applied to Vancomycin. <i>Journal of Pharmaceutical Sciences</i> , <b>2016</b> , 105, 2180-7	3.9	13
20	Therapeutic drug monitoring and pharmacokinetics/pharmacodynamics of antibiotics as useful tools for translational research and personalized medicine. <i>Clinical Pharmacokinetics</i> , <b>2015</b> , 54, 885-6	6.2	1
19	Relevance of antibacterial distribution: the particular case of bone penetration. <i>Clinical Pharmacokinetics</i> , <b>2009</b> , 48, 129-30	6.2	1
18	Vancomycin dosage optimization in patients with malignant haematological disease by pharmacokinetic/pharmacodynamic analysis. <i>Clinical Pharmacokinetics</i> , <b>2009</b> , 48, 273-80	6.2	20
17	Pulmonary versus systemic delivery of levofloxacin. The isolated lung of the rat as experimental approach for assessing pulmonary inhalation. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2008</b> , 21, 298-305	3.5	17
16	Development and validation of an HPLC method for vancomycin and its application to a pharmacokinetic study. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , <b>2008</b> , 48, 835-9	3.5	47
15	Pharmacokinetic/pharmacodynamic analysis of vancomycin in ICU patients. <i>Intensive Care Medicine</i> , <b>2007</b> , 33, 279-85	14.5	123
14	Disposition of linezolid in the isolated rat lung after systemic and pulmonary drug delivery. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2007</b> , 60, 1074-9	5.1	8
13	Pulmonary versus systemic delivery of antibiotics: comparison of vancomycin dispositions in the isolated rat lung. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2007</b> , 51, 3771-4	5.9	19
12	Comparative study of the disposition of levofloxacin, netilmicin and cefepime in the isolated rat lung. <i>Journal of Pharmacy and Pharmacology</i> , <b>2005</b> , 57, 861-7	4.8	2
11	Pharmacokinetics and pharmacodynamics of levofloxacin in intensive care patients. <i>Clinical Pharmacokinetics</i> , <b>2005</b> , 44, 627-35	6.2	15
10	New formulations of amoxicillin/clavulanic acid: a pharmacokinetic and pharmacodynamic review. <i>Clinical Pharmacokinetics</i> , <b>2005</b> , 44, 1097-115	6.2	25
9	Influence of flow rate on the disposition of levofloxacin and netilmicin in the isolated rat lung. <i>European Journal of Pharmaceutical Sciences</i> , <b>2005</b> , 24, 325-32	5.1	5

8	Influence of the infusion rate on disposition of netilmicin in the isolated rat perfused kidney. <i>European Journal of Pharmaceutical Sciences</i> , <b>2002</b> , 16, 133-41	5.1	3
7	Influence of dose on the disposition kinetics of netilmicin in the isolated kidney of the rat. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , <b>2002</b> , 27, 127-33	2.7	1
6	In vitro study of experimental factors affecting the microdialysis results. <i>Analytica Chimica Acta</i> , <b>2002</b> , 459, 143-150	6.6	11
5	Pharmacokinetic/pharmacodynamic modelling of ciprofloxacin 250 mg/12 h versus 500 mg/24 h for urinary infections. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2002</b> , 50, 67-72	5.1	12
4	Pharmacokinetics of ciprofloxacin as a tool to optimise dosage schedules in community patients. <i>Clinical Pharmacokinetics</i> , <b>2002</b> , 41, 1213-20	6.2	8
3	A retrospective analysis of pharmacokinetic-pharmacodynamic parameters as indicators of the clinical efficacy of ceftizoxime. <i>Clinical Pharmacokinetics</i> , <b>2001</b> , 40, 125-34	6.2	5
2	Distribution of ciprofloxacin in the isolated rat lung in the presence and absence of tissue oedema. <i>European Journal of Pharmaceutical Sciences</i> , <b>1999</b> , 8, 203-9	5.1	8
1	Basis of anti-infective therapy: pharmacokinetic-pharmacodynamic criteria and methodology for dual dosage individualisation. <i>Clinical Pharmacokinetics</i> , <b>1999</b> , 37, 289-304	6.2	20